Parkinson's disease is a neurodegenerative disorder that affects movement and can lead to tremors, stiffness, and difficulty with balance. It is caused by the buildup of abnormal protein called alpha-synuclein in nerve cells in the brain.
The Syn-One Test developed by CND Life Sciences uses skin samples to detect this protein buildup accurately.
Parkinson's disease is a neurodegenerative disorder that affects movement and can lead to tremors, stiffness, and difficulty with balance. It is caused by the buildup of abnormal protein called alpha-synuclein in nerve cells in the brain. The Syn-One Test developed by CND Life Sciences uses skin samples to detect this protein buildup accurately.
The Syn-One Test accurately detected a buildup of proteins in the nerves that indicated Parkinson's disease in 93% of participants.
Along with helping diagnose Parkinson's early, the Syn-One Test can also rule out other diseases that have similar symptoms. One study showed that patients with Parkinson's were often misdiagnosed over 20% of them.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(30%)
The article is deceptive in several ways. Firstly, it states that the Syn-One Test accurately detected a buildup of proteins in the nerves that indicated Parkinson's disease in 93% of participants. However, this statement is misleading because it implies that the test can diagnose Parkinson's disease with certainty when in fact, no diagnostic tool has been proven to do so. Secondly, the article states that a spinal fluid test already exists and others are developing tests that detect the disease from blood, tears and nasal swabs. However, this statement is also misleading because it implies that these tests can diagnose Parkinson's disease with certainty when in fact they have not been proven to do so. Lastly, the article states that a half million people are diagnosed with Parkinson's disease but the number of actual cases is likely higher. However, this statement is misleading because it implies that there is an accurate way to determine the number of actual cases which has not been established.
The Syn-One Test accurately detected a buildup of proteins in the nerves that indicated Parkinson's disease in 93% of participants.
Fallacies
(85%)
The article contains several fallacies. The first is an appeal to authority when it quotes Dr. Joseph Jankovic stating that the skin test is a window into the brain and specifically looks for an abnormal protein linked to degenerative brain disorders called phosphorylated alpha-synuclein, or P-SYN. This statement implies that this doctor has expertise in this area, but it does not provide any evidence of his qualifications or credentials. The second fallacy is a dichotomous depiction when the article states that early detection of Parkinson's disease can help diagnose it earlier and slow down its progression with drug treatment. This statement implies that there are only two options for treating Parkinson's disease, which is not true as other treatments exist. The third fallacy is inflammatory rhetoric when the article states that about a half million people are diagnosed with Parkinson's disease, but the number of actual cases is likely higher. This statement implies that there is something wrong or negative about having more cases of Parkinson's disease than what has been officially diagnosed.
The skin test basically is a window into the brain,
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (50%)
Gina Carey has a conflict of interest on the topic of skin test and phosphorylated alpha-synuclein (P-SYN) as she is affiliated with CND Life Sciences CEO Rick Morello who owns Syn-One Test which is mentioned in the article.
Gina Carey mentions that a new study has found that skin tests may be able to detect early signs of Parkinson's disease. She then goes on to mention Syn-One Test, a company owned by CND Life Sciences CEO Rick Morello who is also affiliated with Gina Carey.
Gina Carey mentions the importance of diagnosing and treating neurodegenerative disorders such as Parkinson's disease. She then goes on to mention Syn-One Test which is mentioned in the article.
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of phosphorylated alpha-synuclein (P-SYN) as they are affiliated with CND Life Sciences CEO Rick Morello who is involved in developing Syn-One Test which measures P-SYN levels.
The article mentions that CND Life Sciences, a company founded by Rick Morello, has developed the Syn-One test. The author does not disclose their affiliation with this company or any potential conflicts of interest they may have.
A simple skin biopsy test, the Syn-One Test, can detect an abnormal form of alpha-synuclein with high accuracy in individuals with neurodegenerative disorders such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF)
The test identified phosphorylated alpha-synuclein (P-SYN) with 95.5% accuracy in a blinded, multicenter trial
Synucleinopathies include PD, DLB, MSA, and PAF
Each year, there are nearly 200,000 people in the U.S. who face a diagnosis of Parkinson's disease (PD), dementia with Lewy bodies (DLB), and related disorders
Patients often experience delays in diagnosis or are misdiagnosed due to the complexity of synucleinopathies
The test can offer better diagnostic answers and care for patients by identifying the underlying pathology of synucleinopathies more objectively
Accuracy
The Syn-One Test accurately detected a buildup of proteins in the nerves that indicated Parkinson's disease in 93% of participants.
Along with helping diagnose Parkinson's early, the Syn-One Test can also rule out other diseases that have similar symptoms. One study showed that patients with Parkinson's were often misdiagnosed over 20% of them.
Deception
(50%)
The article is deceptive in several ways. Firstly, the title of the article suggests that it will be discussing all neurodegenerative disorders when in fact it only discusses synucleinopathies which include Parkinson's disease and other related conditions. Secondly, the author claims that this skin test can accurately detect these diseases with high accuracy but fails to mention any limitations or potential false positives of the test. Thirdly, the article quotes a study that found 95.5% accuracy in identifying phosphorylated alpha-synuclein (P-SYN) which is an abnormal protein found in cutaneous nerve fibers and all synucleinopathies but fails to mention any other studies or research on this topic. Lastly, the article quotes a study that included 428 adults aged 40-99 years recruited from various neurology practices across the United States without providing any information about how these participants were selected or what criteria they met for inclusion in the study.
The title of the article suggests it will discuss all neurodegenerative disorders when in fact it only discusses synucleinopathies which include Parkinson's disease and other related conditions. This is a lie by omission.
Fallacies
(85%)
The article contains an appeal to authority fallacy by stating that the study was published in JAMA and citing a professor of neurology at Harvard Medical School as a source. The author also uses inflammatory rhetoric when describing synucleinopathies as 'progressive neurodegenerative diseases with varying prognoses'. Additionally, there is an example of dichotomous depiction in the statement that patients often experience delays in diagnosis or are misdiagnosed due to the complexity of synucleinopathies. However, no other fallacies were found.
The study was published online on March 20 in JAMA.
Bias
(85%)
The article is biased towards the Syn-One Test developed by CND Life Sciences. The author mentions that the test was used to analyze levels of P-SYN via skin biopsies and states that it detected P-SYN in 95.5% of study participants overall, including all disease groups except for controls with no synucleinopathy who tested positive at a rate of only 3.3%. The author also mentions the company outside the submitted work.
Investigators said it is possible that some of the controls who tested positive had a subclinical form of synucleinopathy, which would explain the false positives.
The author mentions CND Life Sciences outside the submitted work.
The Syn-One Test was used to analyze levels of P-SYN via skin biopsies
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
The author has a conflict of interest on the topic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The article mentions that the skin test is accurate in detecting PD and DLB. However, it does not disclose any financial ties or personal relationships between the author and companies or organizations related to these diseases.
The article states that 'the skin test accurately detected Parkinson's disease (PD) and dementia with Lewy bodies (DLB)'.
A study has found that Parkinson's disease can be detected through the analysis of skin samples.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(50%)
The article is deceptive in several ways. Firstly, the title implies that Parkinson's disease can be detected through skin when in fact it cannot. Secondly, the author quotes a study saying that 'Parkinsons-like symptoms could be detected by measuring electrical signals from sweat glands', but this statement is misleading as there are no studies to support this claim.
The author quotes a study saying 'Parkinsons-like symptoms could be detected by measuring electrical signals from sweat glands', but this statement is misleading as there are no studies to support this claim.
The title implies that Parkinson's disease can be detected through skin when in fact it cannot.
Fallacies
(85%)
The article contains an appeal to authority fallacy by stating that a study has found something without providing any evidence or context for the study. The author also uses inflammatory rhetoric when they describe Parkinson's disease as 'debilitating'. Additionally, there is no clear distinction between formal and informal fallacies in this article.
Latest U.S. World Politics Entertainment HealthWatch MoneyWatch Crime Sports Local News Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News Streaming
Parkinson's disease is a debilitating condition that affects millions of people worldwide.
Bias
(0%)
The article is highly biased. The author uses language that dehumanizes people with Parkinson's disease by describing them as having a 'condition'. This implies that they are somehow less than human or abnormal.
]Latest U.S. World Politics Entertainment HealthWatch MoneyWatch Crime Sports Local News Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News Streaming Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Shows 48 Hours 60 Minutes America Decides CBS Evening News CBS Mornings CBS News Eye on America CBS News Mornings CBSCBS Reports CBSSaturday Morning The Dish Face the Nation Here Comes the Sun Person to Person Prime Time Sunday Morning The Takeout The Uplift Weekender Photos Podcasts In Depth Newsletters Download Our App
Valley doctors have created a first-of-its-kind test that uses a skin sample to diagnose diseases like Parkinson's disease and dementia
The Syn-One Test accurately detected a buildup of proteins in the nerves that indicated Parkinson's disease in 93% of participants.
A simple skin biopsy test, the Syn-One Test, can detect an abnormal form of alpha-synuclein with high accuracy in individuals with neurodegenerative disorders such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and pure autonomic failure (PAF)
Parkinson's disease can be detected through skin.
The Syn-One Test identified phosphorylated alpha-synuclein (P-SYN) with 95.5% accuracy in a blinded, multicenter trial
Synucleinopathies include Parkinson's disease, dementia with Lewy bodies, and related disorders
Accuracy
The test identified phosphorylated alpha-synuclein (P-SYN) with 95.5% accuracy in a blinded, multicenter trial
Synucleinopathies include PD, DLB, MSA, and PAF
Deception
(50%)
The article is deceptive in several ways. Firstly, the title claims that the test can detect diseases like Parkinson's or dementia when it only provides a quicker and more accurate diagnosis of these conditions. Secondly, the author quotes Dr. Todd Levine as saying that there are no stitches required for this procedure when in fact they mention later on in the article that patients will need to wear a bandage over their skin sample until it heals up like a scab over the next few weeks. Lastly, while the test may be less invasive than other tests available, it is not clear if there are any long-term risks associated with this procedure.
Dr. Todd Levine is quoted as saying there are no stitches required for this procedure, but later on in the article they mention that patients will need to wear a bandage over their skin sample until it heals up like a scab over the next few weeks.
The test may be less invasive than other tests available, but it is not clear if there are any long-term risks associated with this procedure.
The title claims that the test can detect diseases like Parkinson's or dementia when in fact it only provides a quicker and more accurate diagnosis of these conditions.
Fallacies
(100%)
None Found At Time Of
Publication
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
The author has a financial tie to the company that developed the skin test. The article mentions Dr. Todd Levine as Chief Medical Officer at CND Life Sciences and does not disclose any potential conflicts of interest.
